Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Emergent BioSolutions Inc.NYSE: EBS

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $14.4M (cash outflow) rose 166.7% year over year, ahead of the -51.7% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -15.7% a year.

Context

  • Accounts payables amounted to 1.1% of revenue in FY2025, down 2.0 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +166.7% holds above the trailing-twelve-month pace of -51.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14.4M-226.3% QoQ
Last fiscal yearDec 2025
-$8.4M-74.5% YoY
LTMMar 2026
-$17.4M-51.7% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+166.7%——
1 year-74.5%——
3-year CAGR-15.7%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(8.4M) USD
Year-over-year change
+74.5%

Accounts Payables vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -51.7% is the 6th highest of 10, against a peer median of +110.0%.
  • Accounts payables amounts to 2.6% of revenue for EBS, versus a peer median of 0.7%.
EBS Competitors
Accounts Payables for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRTAProthena Corporation plcLTM Mar 2026$18.91M USD+528.3%—32.6%
EBSEmergent BioSolutions Inc.LTM Mar 2026$17.4M USD-51.7%-15.7%2.6%
SIGASIGA Technologies, Inc.LTM Mar 2026$7M USD-186.0%—7.5%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$3.59M USD-108.2%+55.1%0.9%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$3.39M USD+1225.9%——
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$3.23M USD+147.7%+135.7%—
CMPSCOMPASS Pathways plcLTM Mar 2026$1.81M USD+305.3%-6.6%—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$532K USD+110.0%+0.6%0.2%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$355K USD-110.4%+128.7%0.7%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$35K USD-92.7%—0.0%
SNDLSNDL Inc.LTM Mar 2026CA$0 CAD——0.0%
Peer median (excluding EBS) —+110.0%+55.1%0.7%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income230.9M(211.6M)(760.5M)(190.6M)52.6M
Depreciation & Amortization123.8M143.3M125.1M108.8M95.8M
Deferred Income Tax46.9M(28.6M)(8.9M)(5.5M)(4M)
Stock-Based Compensation42.4M45.1M23.1M18M16.2M
Change in Working Capital(156.4M)(2.1M)(70.3M)88.7M(22.4M)
Accounts Receivables(48.2M)118.1M(21.6M)(24.4M)25.5M
Inventory(44M)(57.1M)600K(24.5M)(30.3M)
Accounts Payables(2.5M)(14M)10.6M(33M)(8.4M)
Other Working Capital(61.7M)(49.1M)(59.9M)170.6M(9.2M)
Other Non-Cash Items33.5M19.8M485.2M39.3M32.4M
Operating Cash Flow321.1M(34.1M)(206.3M)58.7M170.6M
Capital Expenditures(225M)(115.8M)(51.6M)(22.9M)(13.8M)
Acquisitions (Net)00270.2M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(265.5M)(6.3M)148.1M83.2M
Investing Cash Flow(225M)(381.3M)212.3M125.2M69.4M
Debt Repayment(35.9M)564.2M(543.4M)(198.4M)(112.5M)
Common Stock Issued008.4M9.3M2.2M
Common Stock Repurchased(106M)(82.1M)00(24.9M)
Dividends Paid00000
Other Financing Activities900K(900K)(700K)(900K)(1.4M)
Financing Cash Flow(141M)481.2M(535.7M)(190M)(136.6M)
Effect of Forex Changes(300K)500K(1.2M)0100K
Net Change in Cash(45.2M)66.3M(530.9M)(6.1M)103.5M
Free Cash Flow96.1M(149.9M)(257.9M)35.8M156.8M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.